Ottolini M G, Porter D D, Hemming V G, Zimmerman M N, Schwab N M, Prince G A
Department of Pediatrics, F Edward Herbert School of Medicine, The Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Bone Marrow Transplant. 1999 Jul;24(1):41-5. doi: 10.1038/sj.bmt.1701813.
Respiratory syncytial virus (RSV) has emerged as a leading cause of pneumonia, with high mortality, in bone marrow transplant (BMT) recipients, as well as in other profoundly immunocompromised patients, such as myelosuppressed adults with leukemia. We tested the efficacy of immunoglobulin with high anti-RSV neutralizing antibody levels (RSVIG) for prophylaxis and therapy of RSV infection in cotton rats undergoing prolonged immunosuppression with cyclophosphamide. These animals experience persistent infection, a model which is similar to the disease seen in post-BMT humans. Both prophylaxis and therapy reduced pulmonary viral replication over 500-fold to nearly undetectable levels. In animals receiving continual immunosuppression, the use of multiple therapeutic doses of RSVIG was able to prevent rebound viral replication, though virus was not completely eliminated.
呼吸道合胞病毒（RSV）已成为骨髓移植（BMT）受者以及其他严重免疫功能低下患者（如患有白血病的骨髓抑制成人）肺炎的主要病因，且死亡率很高。我们测试了具有高抗RSV中和抗体水平的免疫球蛋白（RSVIG）对接受环磷酰胺长期免疫抑制的棉鼠预防和治疗RSV感染的疗效。这些动物会经历持续感染，这一模型与BMT后人类所患疾病相似。预防和治疗均使肺部病毒复制减少了500倍以上，降至几乎检测不到的水平。在持续接受免疫抑制的动物中，使用多个治疗剂量的RSVIG能够预防病毒复制反弹，尽管病毒并未被完全清除。
